Key result
Second-line ifosfamide demonstrates good tolerability following doxorubicin progression in metastatic vaginal leiomyosarcoma.
Why the study?
Vaginal leiomyosarcoma is an atypical, rare entity with limited data, often misdiagnosed or detected late, lacking standard treatment protocols.
Case Report (n=1)
No
Vaginal leiomyosarcoma is a rare malignancy that often presents with nonspecific symptoms leading to delayed diagnosis, highlighting the need for individualized, multidisciplinary care.
Answers are grounded in this paper and cite their sources.
May inform ifosfamide use after doxorubicin progression in rare vaginal leiomyosarcoma; leaves open prospective validation.
Leiomyosarcoma (LMS) is a rare malignant tumor derived from smooth muscle cells. It usually occurs in the uterine cavity, other localizations, such as vaginal leiomyosarcoma, are atypical. Due to the nonspecific nature of its clinical presentation, vaginal LMS may be misdiagnosed as a benign gynecological neoplasm and is often detected at an advanced stage. Here we report a case of a 45-year-old patient who was diagnosed with metastatic vaginal LMS at the regional oncology center of Oujda in Morocco. Following the multidisciplinary team meeting discussion, the patient received first-line doxorubicin-based chemotherapy. Due to the progression of the disease in the lungs, the patient received second- line ifosfamide-based treatment, with an excellent tolerance. Based on our case and a review of the literature, the vaginal localization of leiomyosarcoma remains exceptional. Diagnosis is essentially based on histology, and immunohistochemical complementation is always necessary to rule out other diagnoses. The disease's nonspecific symptoms often delay diagnosis. Treatment must be individualized and should always be discussed in a multidisciplinary meeting. In localized stages, the mainstay of treatment is surgery, combined with chemotherapy and radiotherapy. In advanced stages, treatment is mainly based on chemotherapy. Targeted therapies and immunotherapy are under investigation as promising treatments for leiomyosarcoma. This case report enriches the limited data on vaginal leiomyosarcoma. Vaginal presentation of leiomyosarcoma remains uncommon. Due to the nonspecific symptoms of the disease, diagnosis is often delayed. This leads to a worse prognosis. The rarity of leiomyosarcoma also makes it difficult to treat, as no standard treatment protocol exists.
No takes yet. Share an insight, caveat, or question.
Jebrouni et al. (2025) conducted a case report in Primary vaginal leiomyosarcoma (n=1). Doxorubicin followed by ifosfamide was evaluated on Treatment response and tolerance. A 45-year-old woman with metastatic primary vaginal leiomyosarcoma experienced disease progression after first-line doxorubicin but tolerated second-line ifosfamide therapy well.
Synapse has enriched 10 related papers. Consider them for comparative context: